Analysis of APAF-1 expression in human cutaneous melanoma progression

被引:50
作者
Baldi, A
Santini, D
Russo, P
Catricalà, C
Amantea, A
Picardo, M
Tatangelo, F
Botti, G
Dragonetti, E
Murace, R
Tonini, G
Natali, PG
Baldi, F
Paggi, MG
机构
[1] Regina Elena Inst Canc Res, Ctr Expt Res, I-00158 Rome, Italy
[2] Univ Naples 2, Sect Pathol, Dept Biochem & Biophys F Cedrangolo, Naples, Italy
[3] Sect Oncol, Rome, Italy
[4] San Gallicano Dermatol Inst, Rome, Italy
[5] Natl Canc Inst, Naples, Italy
[6] Diagnost Ctr San Raffaele Termini, Rome, Italy
[7] IML, Aeronaut Mil, Rome, Italy
关键词
APAF-1; melanoma; tumor progression;
D O I
10.1111/j.0906-6705.2004.00136.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
APAF-1 plays a pivotal role in mitochondria-dependent apoptosis, binding to cytochrome c and favoring activation of caspase-9. It has been shown that epigenetic silencing of the APAF-1 gene is a common event in several metastatic melanoma cells in vitro. We determined, by Western blot, variation in the level of expression of APAF-1 in several human melanoma cell lines and, by immunohistochemistry, in a group of 106 histological samples including benign and malignant melanocytic lesions. We observed APAF-1 down-regulation or loss of expression in two metastatic melanoma cell lines, compared to primary melanoma cell lines. The immunohistochemical analysis revealed a significant difference in APAF-1 staining between nevi and melanomas. In addition, we found a significant negative correlation between APAF-1 expression level and tumor thickness and between primary melanomas and metastases. We conclude that loss of APAF-1 expression can be considered as an indicator of malignant transformation in melanoma.
引用
收藏
页码:93 / 97
页数:5
相关论文
共 19 条
  • [1] Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
    Balch, CM
    Soong, SJ
    Gershenwald, JE
    Thompson, JF
    Reintgen, DS
    Cascinelli, N
    Urist, M
    McMasters, KM
    Ross, MI
    Kirkwood, JM
    Atkins, MB
    Thompson, JA
    Coit, DG
    Byrd, D
    Desmond, R
    Zhang, YT
    Liu, PY
    Lyman, GH
    Morabito, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) : 3622 - 3634
  • [2] Expression of AP-2 transcription factor and of its downstream target genes c-kit, E-cadherin and p21 in human cutaneous melanoma
    Baldi, A
    Santini, D
    Battista, T
    Dragonetti, E
    Ferranti, G
    Petitti, T
    Groeger, AM
    Angelini, A
    Rossiello, R
    Baldi, F
    Natali, PG
    Paggi, MG
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2001, 83 (03) : 364 - 372
  • [3] BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO
  • [4] 2-C
  • [6] LOSS OF HETEROZYGOSITY OF DQ-ALPHA GENE IN HUMAN-MALIGNANT MELANOMA
    CASTELLI, C
    MAZZUCCHELLI, F
    SENSI, M
    FOSSATI, G
    PARMIANI, G
    [J]. TUMORI, 1989, 75 (04) : 378 - 382
  • [7] Apaf1 and the apoptotic machinery
    Cecconi, F
    [J]. CELL DEATH AND DIFFERENTIATION, 1999, 6 (11) : 1087 - 1098
  • [8] CHATTOPADHYAY P, 1991, CANCER RES, V51, P3183
  • [9] Pro-apoptotic apoptosis protease-activating factor 1 (Apaf-1) has a cytoplasmic localization distinct from Bcl-2 or Bcl-xL
    Hausmann, G
    O'Reilly, LA
    van Driel, R
    Beaumont, JC
    Strasser, A
    Adams, JM
    Huang, DCS
    [J]. JOURNAL OF CELL BIOLOGY, 2000, 149 (03) : 623 - 633
  • [10] Drug-resistance in human melanoma
    Helmbach, H
    Rossmann, E
    Kern, MA
    Schadendorf, D
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (05) : 617 - 622